NEUTROLIS
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapy on the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and s... upported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.
NEUTROLIS
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.neutrolis.com
Total Employee:
1+
Status:
Active
Total Funding:
23.14 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins Sitelinks Search Box Organization Schema
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Imago BioSciences
Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Third Harmonic Bio
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Current Employees Featured
Founder
Investors List
Prefix Capital
Prefix Capital investment in Venture Round - Neutrolis
Official Site Inspections
http://www.neutrolis.com Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Neutrolis"
Neutrolis
Neutrolis aims to transform patients' lives and revolutionize the treatment of autoimmune and inflammatory diseases by creating precision therapies to target NETs. Overactive neutrophils …See details»
About - Neutrolis
Neutrolis is a clinical stage company developing a robust pipeline of therapeutics in major disease areas driven by NET-based pathologies starting with lupus. Toby is co-founder, CEO, CSO …See details»
Neutrolis - Crunchbase Company Profile & Funding
Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that …See details»
Patients - neutrolis.com
Neutrolis is the leading therapeutics company addressing neutrophil-based diseases starting with Neutrophil Extracellular Traps (NETs) and other sources of pathologic extracellular DNA. …See details»
Neutrolis Company Profile 2024: Valuation, Funding & Investors
Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body.See details»
Neutrolis Inc - LinkedIn
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular...See details»
Resident Company Q&A: Neutrolis - LabCentral | Cambridge, MA
Oct 26, 2021 · As we continue to highlight the groundbreaking work of LabCentral resident and alumni biotech companies, here’s a snapshot of Neutrolis, Inc., a preclinical-stage resident …See details»
Neutrolis - Funding, Financials, Valuation & Investors - Crunchbase
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).See details»
Neutrolis - Contacts, Employees, Board Members, Advisors & Alumni
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).See details»
Neutrolis Inc: Contact Details and Business Profile
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil …See details»
Neutrolis - Overview, News & Similar companies | ZoomInfo.com
Aug 3, 2020 · Neutrolis contact info: Phone number: (617) 863-3650 Website: www.neutrolis.com What does Neutrolis do? Neutrolis, Inc. is a biotechnology company developing therapeutics …See details»
Platform - Neutrolis
Neutrolis’ pioneering science, paired with powerful exDNASEâ„¢ design and manufacturing capabilities, underpins our unique therapeutics platform. Our proprietary exDNASEâ„¢ platform …See details»
Neutrolis - VentureRadar
Neutrolis aims to transform patients' lives and revolutionize the treatment of autoimmune and inflammatory diseases by creating precision therapies to target NETs. Neutrolis' platform …See details»
Neutrolis - Work in biotech
Neutrolis is a clinical-stage company focused on developing innovative therapies that target neutrophils, the most abundant immune cells in the body. Their research centers around …See details»
Neutrolis announces development of enzyme for severe COVID-19
Aug 7, 2020 · Neutrolis, a biotechnology company developing therapeutics that target neutrophils, has announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that …See details»
Contact - Neutrolis
Neutrolis is actively looking for collaborators of all types to help us achieve our broad company vision and drive patient impact. Please contact us. Get in touch!See details»
Neutrolis Announces Development Of First-In-Class Treatment …
Aug 3, 2020 · Neutrolis is a biotechnology company developing first-in-class therapies that target neutrophils and their pathogenic products, including NETs. Neutrolis' proprietary platform, …See details»
Neutrolis announces development of first-in-class therapy to …
Aug 5, 2020 · Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, …See details»
Pipeline - Neutrolis
Our pipeline of therapeutics is being developed to specifically target the causative pathological mechanisms of a number of NETs-based diseases and beyond. Neutrolis’ unique approach …See details»
Neutrolis Develops Treatment Targeting NETs for Patients with …
Aug 7, 2020 · Neutrolis announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular …See details»